The terminal differentiation of Ob 1771 pre-adipose cells induced by arachidonic acid in serum-free hormone-supplemented medium containing insulin, transferrin, growth hormone, tri-iodothyronine and fetuin (5F medium) was strongly diminished in the presence of inhibitors of prostaglandin synthesis, namely aspirin or indomethacin. Carbaprostacyclin, a stable analogue of prostacyclin (prostaglandin 12) known to be synthesized by pre-adipocytes and adipocytes, behaved as an efficient activator of cyclic AMP production and was able, when added to 5F medium, to mimic the adipogenic effect of arachidonic acid. Prostaglandins E2, 2,2 and D2, unable to affect the cyclic AMP production, failed to substitute for carbaprostacylin. However, prostaglandin F which is another metabolite of arachidonic acid in pre-adipose and adipose cells, able to promote inositol phospholipid breakdown and protein kinase C activation, potentiated the adipogenic effect of carbaprostacyclin. In addition, carbaprostacyclin enhanced both a limited proliferation and terminal differentiation of adipose precursor cells isolated from rodent and human adipose tissues maintained in primary culture. These results demonstrate the critical role of prostacyclin and prostaglandin F2. on adipose conversion in vitro and suggest a paracrine/autocrine role of both prostanoids in the development of adipose tissue in vivo.
INTRODUCTION
The process of adipose conversion has been delineated in vitro with the use mainly of rodent pre-adipocytes from established cell lines [1] . Early events, such as the emergence of lipoprotein lipase, are triggered by growth arrest [2, 3] , whereas expression of late phenotypes, such as glycerol-3-phosphate dehydrogenase (GPDH) and triacylglycerol accumulation, requires a limited proliferation of these cells expressing early markers of differentiation. This situation, in agreement with data obtained in vivo [4, 5] , strongly suggests that dormant precursor cells already committed can generate new mature fat-cells upon stimulation by specific mitogens. In order to test this hypothesis and to gain a better understanding of the factors involved in the control of this process, serum-free media have been defined [6] [7] [8] [9] . We have recently shown, using Ob 1771 mouse pre-adipocyte cells maintained in a serum-free hormone-supplemented medium [5F medium containing insulin, transferrin, growth hormone (GH), tri-iodothyronine (T3) and fetuin], that post-confluent mitoses and terminal adipose differentiation were strictly controlled by cyclic AMP and modulated by messengers generated through hydrolysis of inositol phospholipids [10] . Furthermore, arachidonic acid appeared to be one of the non-protein 'adipogenic' factors present in serum [10] . Arachidonic acid, as a promoter of both the cyclic AMP and the inositol phospholipid pathways, was indeed able to trigger terminal differentiation when added to SF medium [10] . We have thus investigated the possible involvement of some arachidonic acid metabolite(s) as physiological effector(s) of this process. In the present paper we report that carbaprostacyclin (cPGI2), a stable analogue of prostacyclin (PGI2) [1 1,12] known to be synthesized by pre-adipocytes and adipocytes [13] [14] [15] [16] [17] , is an efficient activator of cyclic AMP production and a potent effector of adipose conversion for both preadipocytes of established cell lines and adipose precursor cells isolated from rodent and human adipose tissues cultured in serum-free hormone-supplemented media. In addition prostaglandin F2. (PGF2J), which is able to activate the inositol phospholipid breakdown pathway, potentiates the adipogenic effect of cPGI2. EXPERIMENTAL 
Methods
Stock cultures of Ob1771 cells (a subclone of Ob17) [18, 19] and 3T3-F442A cells [20] were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum as previously described [10, [18] [19] [20] . After (3 days) in the same mixture as above supplemented with insulin (5 ,ug/ml), transferrin (10 ,tg/ml), a partially purified kallikrein-like activity from rat submaxillary gland (1 ,ug/ ml) [21] and fibroblast growth factor (25 ng/ml) [6] .
Confluent cells were then shifted to another serum-free medium consisting of Dulbecco's modified Eagle's medium and Ham's F12 medium mixed as above and enriched with sodium ascorbate (100 ItM) and sodium selenite (20 nM) and containing insulin (5 ,tg/ml), transferrin (10,ug/ml), GH (2 nM), T3 (200 pM) and fetuin (500 jtg/ml) [7, 10] Adipose precursor cells present in the stromal-vascular fraction of rodent as well as human adipose tissue (plastic surgical samples) were obtained by collagenase digestion as previously described [8, 9] . Cells were plated in serumsupplemented medium at an initial density of2 x 104 cells/ cm2 (rodent cells) or 105 cells/cm2 (human cells). After attachment and careful washings, cells were fed with a standard medium referred to as ITT medium [8, 9] and containing insulin (5 ,tg/ml), transferrin (10 ,tg/ml) and T3 (200 pM) supplemented or not as indicated in the legend to Fig. 3 . GPDH activity, protein content, cell count, intracellular cyclic AMP content and inositol phospholipid breakdown were determined as previously described [10] . The final concentration of ethanol, used as a vehicle for all compounds tested in this study, never exceeded 1 % and had no effect on either adipose conversion or short-term cellular responses such as the intracellular cyclic AMP content or that of inositol phosphates. Materials All prostaglandins were purchased from Cayman Chemicals (Ann Arbor, MI, U.S.A.). Arachidonic acid, indomethacin, aspirin and 3-isobutyl-1-methylxanthine (IBMX) were products of Sigma Chemical Co. (St. Louis, MO, U.S.A.). The sources of other products have already been given [10] .
RESULTS
Effect of aspirin and indomethacin on adipose conversion induced by arachidonic acid in 0b1771 cells
We first examined the effect of the non-steroidal antiinflammatory drugs, aspirin and indomethacin, on the terminal differentiation of Ob 1771 pre-adipocyte cells maintained in SF medium supplemented with 10 ItMarachidonic acid. These drugs are potent inhibitors of the cyclo-oxygenase that catalyses the conversion of arachidonic acid into prostaglandins [13, 22] . As shown in Table 1 , a 12-day exposure of confluent cells to arachidonic acid in the presence of aspirin or indomethacin led to a strong decrease in the GPDH activity, taken as an enzyme marker of adipose terminal differentiation [1, 5, 10] . Exposure of the cells for 5 h to 10 /aM-indomethacin before arachidonic acid resulted in a more potent inhibition, although shorter times of exposure might also have been effective, according to the data obtained in serum-supplemented medium for prostaglandin synthesis [13] . The decrease observed in the GPDH activity was accompanied by a parallel diminution in the number of differentiated triacylglycerolcontaining cells. Indeed, under our serum-free culture conditions, a fairly good correlation was observed between the number of differentiated triacylglycerolcontaining cells, easily detected under the microscope, and the specific activity of GPDH measured at day 12: a value of 3000 munits/mg of protein or more was the result of one cell doubling within 6 days after confluence, followed by differentiation and leading in a reproducible manner to 98-100 Qo differentiated cells present as a monolayer [10] . The effect of cyclo-oxygenase inhibitors on adipose-cell differentiation induced by arachidonic acid suggested that the suppression of prostanoid synthesis in Ob1771 cells (PGE2 > PGI2 > PGF2. [13] )
should also prevent the initial rise in the cyclic AMP content that proved to be essential for terminal differentiation in serum-free hormone-supplemented medium [10] . It was thus not surprising that indomethacin-treated cells, which became unable to differentiate, did not produce cyclic AMP in response to a 5 min exposure to 10 ,tM-arachidonic acid ( Fig. 1 ).
Effect of prostaglandins on cyclic AMP production in Ob1771 cells
In an attempt to determine the nature of the arachidonic acid metabolite(s) directly involved in the production of cyclic AMP, we examined the effect of various prostanoids on this parameter. Since PGI2 is known to decompose rapidly into a chemically stable but biologically inactive derivative, 6-oxo-PGF1., we took advantage of the availability of a stable analogue of PGI2, namely cPGI2, reported to be active in the prevention of platelet aggregation [11, 12] . As shown in Fig. 1, cPGI2 was a potent activator of cyclic AMP production in Obl 771 cells and, as expected, addition of indomethacin did not prevent this effect. Within 5 min 100 nM-cPGI2 was able to increase the intracellular cyclic AMP content to a value similar to that induced by 10 jtM-arachidonic acid. In contrast, addition of 200 nM-PGD2, -PGE2 or -PGF2, failed to provoke any change in the cyclic AMP content as compared with non-exposed cells. This effect of cPGI2 was in agreement with data showing that prostacyclin stimulates cyclic AMP production in several cell types, including fibroblasts [23] [24] [25] . Induction of terminal differentiation and post-confluent mitoses by carbaprostacyclin When added to SF medium, cPGI2 was also able within 12 days to trigger, in a concentration-dependent Ob1771 cells Cells grown to confluence were washed and preincubated in 5F medium containing 100 ,tM-IBMX. After 5 min the medium was aspirated and the cells were incubated in the same fresh medium as above supplemented as indicated under each column either in the absence (white columns) or in the presence (hatched columns) of 10,uM-indomethacin. After 5 min the medium was again aspirated, and cyclic AMP was extracted and assayed at least in triplicate as described in the Experimental section. Values are the means+ S.E.M. (bars) for [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] determinations in at least three independent experiments. Indomethacin did not affect the basal concentration of cyclic AMP. Abbreviation: AA, arachidonic acid. manner, the terminal differentiation of Ob 1771 cells, as illustrated in Table 2 by the expression of high GPDH activity. The dose-response relationship was similar to that obtained for cyclic AMP production (Fig. 1) . The maximal effect, obtained at 200 nm, led in a very reproducible manner to the differentiation of at least 800 of the cells. As expected, this effect remained unimpaired in the presence of aspirin or indomethacin (Table 2) ; in other words, cPGI2 was able to reverse fully the inhibitory effect of aspirin or indomethacin.
After a 6-day exposure to a maximally effective concentration of cPGI2, the increase in cell number reached values close to 2-fold (Fig. 2) . This situation was in good agreement with our previous results, which showed that one doubling in the cell number within 6 days led to terminal differentiation of all of the cells [10] . It may be noted that results similar to those presented in Table 2 and Fig. 2 (Table 2 and ref. [10] ) were ineffective, at a concentration of 200 nm, in triggering the differentiation of a significant number of cells, whereas PGE1 and 6-oxo-PGE1 promoted the differentiation of a low proportion of cells (15) (16) (17) (18) (19) (20) 0%) ; with the last two prostanoids this ability was probably related to the enhancement of cyclic AMP production (see Fig. 1 for PGE1 ). PGI2 thus appeared as the specific metabolite of arachidonic acid involved, through enhancement of cyclic AMP, in the control of terminal differentiation of Obl 771 cells.
Besides its capacity to increase cyclic AMP production rapidly, arachidonic acid was also found to induce rapidly but moderately inositol phospholipid breakdown in Obi771 cells [10] . Furthermore, we have provided evidence that activation of protein kinase C as well as Ca21 mobilization, provoked by second messengers (diacylglycerol and inositol trisphosphate respectively) generated through hydrolysis of inositol phospholipids [26] , could act in concert with agents elevating cyclic AMP concentrations to amplify adipose conversion. Studies in the presence of cPGI2 were therefore also undertaken.
Potentiation of cPGI2-induced adipose conversion by
PGF2a
It should be recalled that the small but significant release of soluble inositol phosphates induced by 1O /tMarachidonic acid from [3H]inositol-prelabelled Ob1771 cells was entirely prevented by 10,uM-indomethacin [10] .
This observation suggested that at least one metabolite of arachidonic acid was involved in the control of inositol phospholipid hydrolysis. PGF2a, which is known to be synthesized and secreted by pre-adipocytes as well as adipocytes [13] [14] [15] [16] [17] , has already been shown to be a potent agonist of inositol phospholipid hydrolysis in Ob1771 cells (EC50 30 nM, [10] ). In contrast, PGE2 (the major metabolite of arachidonic acid in Obi771 cells [13] ) and PGD2 were inactive. PGI2 could also be excluded as an activator of this pathway since, when added at concentrations up to 1 gM, cPGI2 was unable to provoke in eight separate experiments any release of labelled inositol phosphates. PGF2a thus appeared as the prostanoid responsible for the release of inositol phosphates induced by arachidonic acid. Fig. 3 ).
DISCUSSION
To our knowledge, the above results show for the first time the involvement of PGI2, in the form of its stable analogue, in a process of differentiation. Our results show that cPGI2 behaves as a factor able to trigger growth and differentiation of early marker-containing pre-adipose cells. Both effects are likely to be triggered through the ability of cPGI2, after binding to a specific receptor, to activate adenylate cyclase, since directly increasing the cyclic AMP content by pharmacological means led to limited proliferation and terminal differentiation [10] . It is reasonable to postulate that PGI2, which is actually synthesized by Obl7 [13] and 3T3 preadipocytes [14,151 as well as by human adipose precursor cells [16] , is the mediator of these effects. This mediation probably takes place at low concentrations of PGI2, since this prostanoid has been reported to be more potent by one order of magnitude than the stable analogue cPGI2 as a platelet anti-aggregating agent [12] . The involvement of labile cellular diffusible factor(s) has been suggested to explain the fact that expansion of differentiating adiposecell colonies in media containing bovine serum proceeds via mitoses that occur from the centre, where lipid accumulation starts, to the periphery [28] . Our results support the proposal that PGI2 might play a critical role in that respect, since under our culture conditions addition of the stable analogue led to terminal differentiation of the whole cell population after one cell doubling.
PGF2.1 which is also synthesized by pre-adipocytes [13] [14] [15] [16] , has the ability to activate the inositol phospholipid pathway [10] and to potentiate the effect of cPGI2 in promoting adipose conversion. Thus our results support also the proposal that a potent increase in cyclic AMP production and the activation of protein kinase C are acting in concert to modulate terminal differentiation.
The absence of potentiation of the cPG12-induced differentiation by simultaneous exposure to ionomycin (Table  2 ), in contrast with that observed with other agents elevating cyclic AMP concentrations [10] , would suggest that cPGI2, in addition to its effect on cyclic AMP production, might also be able to elicit directly or indirectly a rise in cytoplasmic Ca21 concentration in a manner independent of inositol phospholipid hydrolysis. This hypothesis is supported by the facts that (i) Ca21 influx is regulated by cyclic AMP in several cell types [29] and (ii) PGE1, which is able to bind to the same cellsurface receptor as prostacyclin [30] induces a rise in both cyclic AMP concentrations and Ca2" influx in 3T3 cells [31] . Additional experiments should allow confirmation of this assumption.
As the result of a combined action of PGI2 and PGF2. (Fig. 4) , the activation of specific protein kinases accounts for most, if not all, of the promoting effect of arachidonic acid on the process of adipose conversion [10] . It is proposed that the model given in Fig. 4 PGF2a [17, 32] . According to this model, besides PGI2
and PGF2, production, the prior mobilization of arachidonic acid, through a phospholipase A2-(PLA2-) rather than a phospholipase C-(PLC-)dependent mechanism should play a central role. This feature takes into account the fact that the amount of diacylglycerol (DAG), generated upon stimulation of the hydrolysis of polyphosphoinositides (PIP2) by a maximally effective con-~~~.
-F .~~.. e T -1 *-;5 . locally produced by other cells such as mature adipocytes could play a similar role as described above. No particular role can be ascribed to PGE2, which is nevertheless the major product of arachidonic acid in both mouse and human adipose precursor cells [18, 23, 24] . Putative positive or negative controls between each of the various signalling pathways are not presented.
A2 via a putative GTP-binding protein (Gp). We further postulate that this mechanism represents an important source of free arachidonic acid in these cells. The nature of the hormonal factors able to trigger arachidonic acid mobilization and prostaglandin synthesis remains an open question, although vasoactive peptides and catecholamines are known to be effectors of these processes in rat as well as in human adipocytes [33] [34] [35] . In vivo, both dormant adipose precursor cells and mature adipocytes, able to synthesize PGI2 and PGF2a [13] [14] [15] [16] [17] , could be the potential targets for these hormonal factors. In any event, once released, these prostanoids could play, in a paracrine/autocrine manner and provided that the appropriate hormonal milieu was present, a critical role in the regulation of terminal differentiation and therefore in the control of adiposetissue cellularity.
